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Nutritional Therapy to
Prevent Dyslipidemia in
Patients Starting
Antiretroviral Therapy for
Human Immunodeficiency Virus*
James H. Stein, MD
Madison, Wisconsin
“As long as a person exercises and exerts himself a lot,
takes care not to eat to the point of being completely full,
and keeps his bowels soft, illness will not come upon him
and his strength will increase.”
—Maimonides, Hilchot Deot 4:15, 12th Century
With the advent of highly active antiretroviral therapy
(HAART), human immunodeficiency virus (HIV) infec-
tion has become a chronic disease. As patients with HIV
live longer, they are at increasing risk for more common
diseases of Western society such as cardiovascular disease
(CVD). Indeed, CVD has the highest age-adjusted mortal-
ity rate among individuals with HIV, second only to
complications of HIV (1). Although aging and traditional
risk factors such as tobacco use and dyslipidemia are major
CVD risk factors for patients with HIV, it is likely that
other factors, including persistent inflammation, viremia,
and immune activation as well as specific HAART medi-
cations increase HIV patients’ risk of CVD. It also is well
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recognized that initiation of HAART is associated with
dyslipidemia (2,3). Dyslipidemia appears to be most dra-
matic after initiation of ritonavir-boosted protease inhibitor
regimens, although newer protease inhibitors such as
atazanavir and darunavir have relatively less adverse lipid
effects. Non-nucleoside reverse transcriptase inhibitors also
cause dyslipidemia, and most patients on HAART receive
protease inhibitors or non-nucleoside reverse transcriptase
inhibitors as the backbone of their multidrug HAART
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tor) and raltegravir (an integrase inhibitor) seem to have
minimal lipid effects, but these agents are less commonly
used in the United States and worldwide. Guidelines for
dyslipidemia emphasize dietary therapy; however, there is
little information about the efficacy of dietary interventions
among patients with HIV (3,4). Previous studies suggested
that the effects of dietary interventions in HIV-infected
patients were modest, but those studies were observational
or small.
In this issue of the Journal, Lazzaretti et al. (5) describe
the important results of a prospective, randomized clinical
trial of a dietary intervention involving 83 HIV-infected
patients beginning their first HAART regimen. The dietary
intervention was based on recommendations from the Na-
tional Cholesterol Education Program (NCEP), which
primarily lower total and low-density lipoprotein (LDL)
cholesterol levels (4). The prescribed diet limited calories to
maintain or reduce weight, restricted fat intake to 25% of
total calories, prescribed an especially low intake of satu-
rated fat, and was high in fiber. The investigators provided
quarterly nutritional guidance from a registered dieti-
cian—an important component of the intervention that
should not be overlooked, because standard clinical practice
usually involves simple dietary recommendations (“eat less
fat”). Behavioral health intervention research emphasizes
that long-term behavioral changes are more likely to occur
when there is repeated reinforcement though contact with
healthcare providers. Methodologically, the authors im-
proved the reliability of 24-h food records by supplementing
them with photographic food records. Their robust statis-
tical analysis focused on the interaction of time by treatment
group.
Participants in this study most commonly were prescribed
a HAART regimen that included zidovudine and lamivu-
dine, nucleoside reverse transcriptase inhibitors that do not
have major lipid effects, and efavirenz. Efavirenz was used in
80% of the patients assigned to diet and 85% of the patients
assigned to the control regimen, with the remaining subjects
predominantly receiving boosted protease inhibitors. The
control group had expected increases in total cholesterol
that were significantly blunted with the dietary intervention
group (p  0.001). In the control group, LDL cholesterol
levels increased with HAART initiation, on average, from
85 to 106 mg/dl, but did not change in diet group (p 
.001). Similarly, triglycerides increased in the control
roup from 134 to 160 mg/dl, but decreased in the dietary
ntervention group from 135 to 101 mg/dl (p  0.001).
oth groups experienced similar increases in HDL choles-
erol levels. These lipid changes are relevant clinically. On a
opulation basis, a 1% reduction in total cholesterol reduces
oronary heart disease risk by approximately 2%, so the 15%
etween arms difference in total cholesterol levels observed
fter 12 months would be expected to lead to a long-term
VD risk reduction of approximately 25% to 30% (4).
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The Diet-HIV Trial March 13, 2012:989–90Participants prescribed the interventional diet had signif-
icantly lower intakes of total calories, total fat, and saturated
fat, with a striking reduction in cholesterol intake, from an
average of 406 to 144 mg daily. The average daily intake of
total cholesterol among the participants was much higher
than consumed in the average American diet. Thus, it is
likely that the high baseline dietary intake of cholesterol
accentuated the reductions in total and LDL cholesterol
levels observed with the intervention, because baseline
saturated fat intake and its reduction were typical of patients
who start a reduced-fat diet. The other dramatic change was
the significant increase in fiber intake, which increased from
a fairly common intake level of approximately 19 g/day to
slightly above that recommended by the NCEP (30 g/day).
Increasing dietary fiber intake by 10 g daily would be
expected to lower LDL cholesterol by approximately 5%.
The observed triglycerides reduction was surprising, be-
cause carbohydrate intake increased. These findings suggest
that the hypertriglyceridemia observed with HAART initi-
ation may not be solely due to insulin resistance. However,
the increase in BMI observed after starting HAART was
significantly blunted in patients on the interventional diet
and the waist-to-hip ratio did not appear to increase as
much, either. These changes would be expected to have
salutary effects on triglycerides as well as inflammation. It
would have been useful if the authors had evaluated changes
in inflammation and markers of immune activation, which
are hypothesized to influence CVD risk in patients with
HIV. Effects on immune activation are especially important
during the immune reconstitution phase of ART initiation.
The insights provided by the dietary intervention are an
important addition to the literature and re-emphasize that
dietary interventions can be as effective as low-dose statin
therapy for preventing and treating dyslipidemia associated
with HAART. The authors hypothesized that the signifi-
cant lipid improvements they observed may have been due
to the patients starting HAART rather than being on
chronic therapy, as in previous lifestyle intervention studies.
That is a plausible and testable hypothesis. It also is likely
that the quality of the dietary intervention (i.e., repeated
contact with dieticians and significant increases in dietary
fiber), the subjects’ high baseline intake of dietary choles-
terol, and the larger sample size may explain why they were
able to observe improvements in lipids when others did not.
I would not be as sanguine as the authors in suggesting that
exercise training does not improve the lipid profile. Previous
studies suggesting that exercise interventions in HIV-infected patients are ineffective were small and did demon-
strate other salutary effects of exercise on markers of CVD
risk, including cardiovascular fitness, endurance, and in one
study, blood pressure and hemoglobin A1C. Patients who
are able to perform regular aerobic exercise would be
expected to have better lipids if the intervention assists with
weight loss or prevents weight gain.
Thus, like the medieval Jewish philosopher and physician
Maimonides suggested, it is likely that patients living with
HIV infection who do not eat too much (i.e., calorie
restriction) and who eat fruits, vegetables, nuts, and whole
grains (i.e., high-fiber, low-cholesterol, and low-fat foods
that keep the “bowels soft”) will benefit by avoiding illness
and improving quality of life. For patients living with HIV
infection, avoiding dyslipidemia also avoids, or at least
delays, use of lipid-lowering medications, which are expen-
sive and are complicated to use in patients on HAART. In
conclusion, the authors are correct; nutritional interventions
can prevent adverse changes in the lipid profile of HIV-
infected patients who start HAART. Their findings em-
phasize the importance of nutritional interventions at the
time of HAART initiation to improve CVD risk factors.
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